Cereno Scientific signs CRO to conduct Phase I study of drug candidate CS014
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that an agreement has been signed with the contract research organization (CRO) Clinical Trial Consultants (CTC) to conduct the Phase I study of CS014. CTC will also provide support in the Phase I preparatory steps including study protocol development and clinical trial application process for the study which will be conducted in Sweden. This first-in-human Phase I study is planned to be initiated during the first half of 2024.“We are very